Emergent BioSolutions announced that a new phase I study has begun at the University of Oxford that will evaluate the use of its modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate as a prime boost to GlaxoSmithKline’s (GSK – Analyst Report) Chimp Adenovirus type 3 Ebola vaccine candidate.
The study will enroll 38 volunteers and be conducted in the UK and is being supported by a grant from the Wellcome Trust and the UK Department for International Development. Emergent BioSolutions manufactured the supply of MVA Ebola Zaire vaccine candidate to be used in this phase I study.
{iframe}http://www.zacks.com/stock/news/175031/emergent-biosolutions-glaxo-initiate-ebola-vaccine-study{/iframe}